Dose escalation with a vessel boost in pancreatic adenocarcinoma treated with neoadjuvant chemoradiation

Howlander, 2014 Siegel, 2012, Cancer statistics, 2012, CA Cancer J Clin, 62, 10, 10.3322/caac.20138 Hartwig, 2011, Pancreatic cancer surgery in the new millennium: Better prediction of outcome, Ann Surg, 254, 311, 10.1097/SLA.0b013e31821fd334 Mayo, 2012, Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent, Cancer, 118, 2674, 10.1002/cncr.26553 Baxter, 2007, Trends in the treatment and outcome of pancreatic cancer in the united states, Ann Surg Oncol, 14, 1320, 10.1245/s10434-006-9249-8 Colbert, 2014, Chemoradiation therapy sequencing for resected pancreatic adenocarcinoma in the National Cancer Data Base, Cancer, 120, 499, 10.1002/cncr.28530 Roland, 2015, Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer, Ann Surg Oncol, 22, 1168, 10.1245/s10434-014-4192-6 Abbott, 2013, The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma, Ann Surg Oncol, 20, S500, 10.1245/s10434-013-2882-0 Al-Hawary, 2014, Pancreatic ductal adenocarcinoma radiology reporting template: Consensus statement of the society of abdominal radiology and the American Pancreatic Association, Gastroenterology, 146, 291, 10.1053/j.gastro.2013.11.004 Pingpank, 2001, Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas, J Gastrointest Surg, 5, 121, 10.1016/S1091-255X(01)80023-8 Stokes, 2011, Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer, Ann Surg Oncol, 18, 619, 10.1245/s10434-010-1456-7 Landry, 2010, Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma, J Surg Oncol, 101, 587, 10.1002/jso.21527 Kim, 2013, A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer, Cancer, 119, 2692, 10.1002/cncr.28117 Arvold, 2012, Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer, Cancer, 118, 3026, 10.1002/cncr.26633 Evans, 2008, Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head, J Clin Oncol, 26, 3496, 10.1200/JCO.2007.15.8634 Kuban, 2008, Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer, Int J Radiat Oncol Biol Phys, 70, 67, 10.1016/j.ijrobp.2007.06.054 Viswanathan, 2009, Increasing brachytherapy dose predicts survival for interstitial and tandem-based radiation for stage IIIB cervical cancer, Int J Gynecol Cancer, 19, 1402, 10.1111/IGC.0b013e3181b62e73 Hall, 2014, The influence of radiation therapy dose escalation on overall survival in unresectable pancreatic adenocarcinoma, J Gastrointest Oncol, 5, 77 Landry, 2002, Treatment of pancreatic cancer tumors with intensity-modulated radiation therapy (IMRT) using the volume at risk approach (VARA): Employing dose-volume histogram (DVH) and normal tissue complication probability (NTCP) to evaluate small bowel toxicity, Med Dosim, 27, 121, 10.1016/S0958-3947(02)00094-8 Rajagopalan, 2013, Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer, Radiat Oncol, 8, 254, 10.1186/1748-717X-8-254 Chuong, 2013, Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated, Int J Radiat Oncol Biol Phys, 86, 516, 10.1016/j.ijrobp.2013.02.022 Hoyer, 2005, Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma, Radiother Oncol, 76, 48, 10.1016/j.radonc.2004.12.022 Vainshtein, 2013, Int J Radiat Oncol Biol Phys, 86, 96, 10.1016/j.ijrobp.2012.11.020 Berger, 2008, Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: A prospective validation by RTOG 9704, J Clin Oncol, 26, 5918, 10.1200/JCO.2008.18.6288 Montgomery, 1997, Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas, Ann Surg Oncol, 4, 551, 10.1007/BF02305535